What happened with RXST today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
RxSight makes the Light Adjustable Lens (LAL), an artificial lens implanted during cataract surgery. After surgery, doctors use its office-based Light Delivery Device (LDD) to apply programmed ultraviolet light that adjusts the lens’s focusing power to customize the patient’s vision.
Ophthalmology practices buy the LDD, while ambulatory surgery centers are the main buyers of LALs. Placing a device enables ongoing lens purchases as doctors treat more patients; lens sales provide most of RxSight’s revenue. Its commercial business is concentrated in the United States, with sales also underway in selected overseas markets.
The business depends on practices investing in the device and then using it regularly, and on patients accepting extra clinic visits and out-of-pocket costs. In the United States, Medicare covers the conventional cataract procedure but not the premium lens’s additional cost, which patients pay; most commercial insurers follow that approach. RxSight must maintain regulatory approvals and cannot promote its products for uses outside their approved indications.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Alcon’s Acrysof lenses compete with RxSight’s LAL for cataract surgeons and patients choosing a replacement lens that also corrects vision. Watch Acrysof demand: in the U.S., patients choosing RxSight’s premium lens pay the extra charges above the conventional procedure covered by Medicare, making willingness to pay important to this rivalry.
Johnson & Johnson’s Tecnis lenses compete directly with RxSight’s LAL for cataract patients choosing replacement lenses with added vision correction, though this market is only a small part of Johnson & Johnson’s diversified business. Watch Tecnis-specific news rather than group results, which also reflect prescription medicines sold to hospitals, healthcare professionals and drug distributors.
Bausch + Lomb sells replacement lenses and cataract surgical products to the same eye-care customers RxSight targets with its light-adjustable lens system. Its Surgical revenue is the closer demand signal to watch—not its larger contact-lens and consumer eye-care business—and accounted for 18% of revenue in 2025.
RxSight, Inc. earningsThis company
RxSight sells adjustable lenses and delivery devices to eye practices and surgery centers, and this report will show whether implants on its installed base can offset weak new-device sales.
Read new light delivery device sales alongside average monthly utilization and lens implants on the installed base. More new devices with rising utilization and implants would show that adoption is widening and existing devices keep generating lens sales; weak placements with falling utilization or implants would show that adoption and recurring lens demand are not yet supporting growth.
Alcon Inc. earningsALC
Alcon’s report will show whether cataract patients are choosing its AcrySof lenses for vision correction, a signal of the competition RxSight’s LAL faces for those patients.
Look for Alcon’s AcrySof demand, not just its group results. Strong demand would show that surgeons and patients continue choosing lenses that compete with RxSight for cataract patients seeking vision correction, keeping competitive pressure in place; weak demand would soften that signal but would not prove patients switched to RxSight’s LAL.
